In basic research Microdialysis is an indispensible tool for drug discovery. CMA’s solutions are used across the globe by drug developers and researchers to achieve fast and efficient drug discovery. CMA´s vision is: To substantially shorten the time-to-market of drug and research projects by offering a complete and leading portfolio of Microdialysis products.
CMA Microdialysis (“CMA”) is a Swedish medical device and research company founded in 1984 as a spin-off from the Karolinska Institute. Unique and market leading solutions are developed, produced and sold to researchers to enable optimized and accelerated drug development. CMA’s complete lines of instruments and consumables are used globally by universities and pharmaceutical companies as unique tools for pre-clinical research.
The core competence lies within solutions based on the Microdialysis technique. The products are produced in Sweden by highly specialized and skilled staff; consumables are manufactured in a clean room environment.
The head office is located outside Stockholm, Sweden. CMA has talented distributors across the globe, responsible for local sales, service and support.
CMA is owned by Harvard Apparatus: Harvard Apparatus was founded in 1901 by Dr. William T. Porter of the Harvard Medical School. Harvard Apparatus developed a name not only for quality but also for innovation. Harvard Apparatus invented the mechanical syringe pump in the 1950s, developed the first small animal Ventilator and introduced the first microprocessor controlled syringe pumps in the 1980s.
Harvard Apparatus is part of the Harvard Bioscience family of companies. Harvard Bioscience (Nasdaq: HBIO) is a global developer, manufacturer and marketer of a broad range of specialized products addressing important research problems in the life sciences. Mr. Erik Düring is the CEO of CMA Microdialysis.
The concept of Microdialysis was born in the early 1970's. While examining the cross-section of a blood vessel among fluorescent nerve endings, Professor Urban Ungerstedt of the Karolinska Institute in Stockholm had the idea of using a dialysis tube as "an artificial blood capillary", in order to monitor chemical events in the tissue, see Microdialysis technique.
The first paper on Microdialysis was published in 1974. Since then, more than 13.000 scientific papers have been published on the technique - among them some 2.000 clinical investigations.
In the pre-clinical research market has CMA been an active and important player for more than 25 years. We have set the standards for probes and instruments in pre-clinical Microdialysis, and I am sure that we will continue to be the market leader in our field of expertise. And we will continue our work to provide the research market with new products that will be part of the very important drug discovery and other fields.
If you have any ideas for new interesting products or research projects, please don´t hesitate to contact me.
Erik Düring, CEO